2.50
Hdl Handle:
http://hdl.handle.net/10755/161625
Type:
Presentation
Title:
Depot-Medroxyprogesterone Acetate and Bone Mineral Density in Premenopausal Women
Abstract:
Depot-Medroxyprogesterone Acetate and Bone Mineral Density in Premenopausal Women
Conference Sponsor:Midwest Nursing Research Society
Conference Year:2002
Author:Clark, Kathleen,
P.I. Institution Name:University of Iowa
Title:Associate Professor
Contact Address:College of Nursing, 101F Nursing Building, Iowa City, IA, 52242, USA
Contact Telephone:3193532121
Osteoporosis increases susceptibility to fracture and is considered a major health problem for women. Although the condition is more common in postmenopausal women, environmental, behavioral and biological factors influencing the attainment and maintenance of bone density during the premenopausal years may account for as much as 2/3 the risk for postmenopausal fracture. Depot-medroxyprogesterone acetate (DMPA) is a progesterone only, contraception that disrupts the hypothalamic-pituitary-ovarian axis and suppresses estradiol concentrations, potentially contributing to loss of bone density. Worldwide, over 3.5 million women use the contraceptive in more than 90 countries. If DMPA contributes to a failure to attain or maintain peak bone density, then its use could increase the risk for osteoporosis and fracture in a substantial number of women. The purpose of this two-year longitudinal study is to determine the effect of DMPA use on bone density in women, aged 18 to 25, and to determine whether any bone loss is attenuated by higher calcium intakes, or can be predicted by estradiol levels, weight gain or vaginal bleeding patterns. Participants include 117 women using DMPA and 89 women using no hormonal method of contraception and are followed every 90 days. At each follow-up visit, bone density is measured, at the femoral neck and lumbar spine, using dual energy x-ray densitometry, serum for estradiol is collected, and dietary calcium is assessed. Vaginal bleeding data is collected prospectively using monthly calendars. At baseline, there was no difference in the mean age, height, weight, body mass index or bone density between DMPA users and non-users. After one year of data collection, bone mineral density at the lumbar spine and femoral neck decreased by 3.7 percent in women using DMPA, as compared to losses of less than 0.5% for controls (P< 0.05).
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Midwest Nursing Research Society

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleDepot-Medroxyprogesterone Acetate and Bone Mineral Density in Premenopausal Womenen_GB
dc.identifier.urihttp://hdl.handle.net/10755/161625-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Depot-Medroxyprogesterone Acetate and Bone Mineral Density in Premenopausal Women</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Midwest Nursing Research Society</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2002</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Clark, Kathleen, </td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Iowa</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">College of Nursing, 101F Nursing Building, Iowa City, IA, 52242, USA</td></tr><tr class="item-phone"><td class="label">Contact Telephone:</td><td class="value">3193532121</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value"> </td></tr><tr><td colspan="2" class="item-abstract">Osteoporosis increases susceptibility to fracture and is considered a major health problem for women. Although the condition is more common in postmenopausal women, environmental, behavioral and biological factors influencing the attainment and maintenance of bone density during the premenopausal years may account for as much as 2/3 the risk for postmenopausal fracture. Depot-medroxyprogesterone acetate (DMPA) is a progesterone only, contraception that disrupts the hypothalamic-pituitary-ovarian axis and suppresses estradiol concentrations, potentially contributing to loss of bone density. Worldwide, over 3.5 million women use the contraceptive in more than 90 countries. If DMPA contributes to a failure to attain or maintain peak bone density, then its use could increase the risk for osteoporosis and fracture in a substantial number of women. The purpose of this two-year longitudinal study is to determine the effect of DMPA use on bone density in women, aged 18 to 25, and to determine whether any bone loss is attenuated by higher calcium intakes, or can be predicted by estradiol levels, weight gain or vaginal bleeding patterns. Participants include 117 women using DMPA and 89 women using no hormonal method of contraception and are followed every 90 days. At each follow-up visit, bone density is measured, at the femoral neck and lumbar spine, using dual energy x-ray densitometry, serum for estradiol is collected, and dietary calcium is assessed. Vaginal bleeding data is collected prospectively using monthly calendars. At baseline, there was no difference in the mean age, height, weight, body mass index or bone density between DMPA users and non-users. After one year of data collection, bone mineral density at the lumbar spine and femoral neck decreased by 3.7 percent in women using DMPA, as compared to losses of less than 0.5% for controls (P&lt; 0.05).</td></tr></table>en_GB
dc.date.available2011-10-26T23:24:28Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T23:24:28Z-
dc.description.sponsorshipMidwest Nursing Research Societyen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.